Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01893879 · ClinicalTrials.gov registry record · NA
Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01893879: Clinical Trial NA study, sponsored by Stanford University.
NCT01893879 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01893879, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This randomized clinical trial studies an investigational drug in preventing lymphedema in patients at high risk after undergoing axillary lymph node dissection. The study drug may prevent lymphedema in patients undergoing axillary lymph node dissection.
Interventions
- OTHER laboratory biomarker analysis
- DRUG placebo for study drug
- DRUG (RS)2-(3-benzoylphenyl)-propionic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01893879
The ClinicalTrials.gov registry entry for NCT01893879 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01893879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01893879 about?
NCT01893879 is a clinical study titled "Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema". This randomized clinical trial studies an investigational drug in preventing lymphedema in patients at high risk after undergoing axillary lymph node dissection. The study drug may prevent lymphedema in patients undergoing axillary lymph node dissection.
What is the current status of trial NCT01893879?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2014-04. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01893879?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo for study drug (DRUG), (RS)2-(3-benzoylphenyl)-propionic acid (DRUG).
Who is sponsoring clinical trial NCT01893879?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.